| 24.66 0.44 (1.82%) | 04-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.55 |
1-year : | 33.82 |
| Resists | First : | 26.15 |
Second : | 28.95 |
| Pivot price | 24.28 |
|||
| Supports | First : | 21.62 | Second : | 17.99 |
| MAs | MA(5) : | 23.36  |
MA(20) : | 24.8 |
| MA(100) : | 26.72 |
MA(250) : | 22.69 |
|
| MACD | MACD : | -1.1 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 55.1 |
D(3) : | 36 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 36.43 | Low : | 13.52 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BEAM ] has closed below upper band by 41.8%. Bollinger Bands are 29.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.03 - 25.13 | 25.13 - 25.23 |
| Low: | 23.28 - 23.38 | 23.38 - 23.49 |
| Close: | 24.49 - 24.67 | 24.67 - 24.86 |
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Sun, 05 Apr 2026
BEAM SEC Filings - Beam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sat, 04 Apr 2026
SG Americas Securities LLC Boosts Beam Therapeutics Stake by 139% - National Today
Sat, 04 Apr 2026
SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Fri, 03 Apr 2026
Beam Therapeutics Inc. (BEAM) interactive stock chart - Yahoo Finance Singapore
Thu, 02 Apr 2026
Beam Therapeutics (BEAM) awards 31,750 RSUs to Chief Medical Officer Amy Simon - Stock Titan
Thu, 02 Apr 2026
CFO of Beam Therapeutics (NASDAQ: BEAM) awarded 31,750 RSUs - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 102 (M) |
| Shares Float | 88 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 104.7 (%) |
| Shares Short | 21,300 (K) |
| Shares Short P.Month | 20,230 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.47 |
| Profit Margin | -57.3 % |
| Operating Margin | -15.3 % |
| Return on Assets (ttm) | -18.6 % |
| Return on Equity (ttm) | -8.2 % |
| Qtrly Rev. Growth | 279.5 % |
| Gross Profit (p.s.) | -2.65 |
| Sales Per Share | 1.37 |
| EBITDA (p.s.) | -3.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -345 (M) |
| Levered Free Cash Flow | -220 (M) |
| PE Ratio | -30.45 |
| PEG Ratio | 0 |
| Price to Book value | 1.97 |
| Price to Sales | 17.97 |
| Price to Cash Flow | -7.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|